Clinical Investigation of the Efficacy and Safety of Anlotinib with Immunotherapy in Advanced Non-Small Cell Lung Cancer as Third-Line Therapy: A Retrospective Study

Overview of attention for article published in Cancer Management and Research, October 2020

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 13 Dimensions

Readers on

mendeley: 8 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 13 publications that cite this research output.

13

The most recent citing publications are shown below. View all 13 publications that cite this research output on Dimensions.

Treatment-related adverse events of immune checkpoint inhibitors combined with angiogenesis inhibitors in advanced lung cancer: A systematic review and meta-analysis

Article in International Immunopharmacology (August 2023)

Anti-Angiogenic Agents Combined with Immunotherapy for Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

Article in Combinatorial Chemistry & High Throughput Screening (August 2023)

Anlotinib: A Novel Molecular-Targeted Drug for Tumours

Article in Journal of Biomedical Nanotechnology (June 2023)